LEO Pharma R&D

LEO Pharma is a foundation-owned, fully-integrated pharmaceutical company dating more than 100 years back.

At LEO Pharma Research & Development (R&D), we discover and develop novel therapies within the LEO focus areas dermatology and critical care, and as one of the world’s leading companies within dermatology, it is our ambition to function as a centre of expertise for the treatment of psoriasis, eczema and actinic keratosis.

We devote our entire R&D efforts to develop innovative drugs within these therapeutic focus areas. Our current R&D projects focus on:

  • Actinic keratosis
  • Eczema
  • Inflammatory indications
  • Nephrology
  • Non-melanoma skin cancer
  • Psoriasis

To ensure sufficient funding for our R&D activities, 14% of LEO Pharma's turnover is allocated to research and development of new drugs.

We use cookies on this website

The cookies help us gain a better understanding of how you use our website; display applications and functionalities, to optimise your website experience, to assign a unique identification number to you, and to help you remember your user ID and password when you return to the website. We also use cookies to generate statistical information.

By continuing to browse our website, you are agreeing to our use of cookies

If you want to know more about our cookie policy and how to avoid and delete cookies click here.